Silencing of PKM2 expression can contribute to radiosensitivity of non-small cell lung cancer (NSCLC)35, moreover, the combination treatment of cisplatin and RNA interference targeting PKM2 can significantly enhance the anti-tumor activity in A549 lung cancer xenograft model36. The gene discussed is PKM; the disease is non-small cell lung carcinoma.